Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 176-187

  Vasquez Bahena D A ^a   Salazar Morales, U E ^a   Ortiz, M I ^b   Castaneda Hernandez G ^a   Troconiz I F ^c  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE HIDALGO   (Mexico)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cyclooxygenase 2; Hyperalgesia; Inflammatory mediators; Pharmacokinetic pharmacodynamic modelling; Time latency

Indexed keywords

CARRAGEENAN; CYCLOOXYGENASE 2; LUMIRACOXIB;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HYPERALGESIA; IN VIVO STUDY; INFLAMMATION; LATENT PERIOD; NONHUMAN; PRIORITY JOURNAL; RAT; THERMAL STIMULATION;

ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; BIOLOGICAL AVAILABILITY; CARRAGEENAN; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERALGESIA; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 74549151010     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00508.x     Document Type: Article

References (50)

1. Ahuja N, Singh A, Singh B (2003). Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 55 : 859 894.
2. Beal SL, Sheiner LB (1982). Estimating population kinetics. CRC Crit Reviews in Bioengineering 8 : 195 222.
3. Beal SL, Sheiner LB (1989-2006). NONMEM Users Guides. GloboMax, Inc. : Hanover, MD.
4. Black JW, Leff P (1983). Operational models of pharmacological agonism. Proc R Soc Lond B 220 : 141 162.
5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 : 1520 1528.
6. Castañeda-Hernández G, Favari L, Hoyo-Vadillo C (1995). Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis. Arzneim-Forsch/Drug Res 45 : 585 589.
7. Crofford LJ (1997). COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 49 : 15 19.
8. Cruz L, Castañeda-Hernández G, Flores-Murrieta FJ, García-López P, Guízar-Sahagún G (2002). Alteration of phenacetin pharmacokinetics after experimental spinal cord injury. Proc West Pharmacol Soc 45 : 4 5.
9. Dayneka NL, Garg V, Jusko WJ (1993). Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21 : 457 478.
10. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA et al. (2005a). Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144 : 538 550.
11. Esser RE, Miserendino-Molteni R, Sharr M, Zhang X, Porter W, Ramos L et al. (2005b). Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. Eur J Pharm Sci 25 : 25 30.
12. Evans AR, Junger H, Southall MD, Nicol GD, Sorkin LS, Broome JT et al. (2000). Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons. J Pharmacol Exp Ther 293 : 912 920.
13. Flores-Murrieta FJ, Ko HC, Flores-Acevedo DM, López-Muñoz FJ, Jusko WJ, Sale ME et al. (1998). Pharmacokinetic-pharmacodynamic modelling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. J Pharmacokinet Biopharm 26 : 547 557.
14. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990). The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265 : 16737 16740.
15. Giraudel JM, Diquelou A, Laroute V, Lees P, Toutain PL (2005). Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. Br J Pharmacol 146 : 642 653.
16. Giuliano F, Warner TD (2002). Origins of prostaglandin E2: involvements of cycloosygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Exp Ther 303 : 1001 1006.
17. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verbug KM et al. (2001). Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96 : 1019 1027.
18. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 : 77 88.
19. Hernández-Díaz S, García-Rodríguez LA (2001). Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 110 (Suppl. 3A 20S 27S.
20. Hinz B, Brune K (2008). Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci 29 : 391 397.
21. Huntjens DR, Danhof M, Della Pasqua OE (2005). Pharmacokinetic- pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology 44 : 846 859.
22. Jain NK, Ishikawa TO, Spigelman I, Herschman HR (2008). COX-2 expression and function in the hyperalgesic response to paw inflammation in mice. Prostaglandins Leukot Essent Fatty Acids 79 : 183 190.
23. Jonsson EN, Karlsson MO (1999). Xpose - an Splus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58 : 51 64.
24. Josa M, Urizar JP, Rapado J, Dios-Viéitez C, Castañeda- Hernández G, Flores-Murrieta F et al. (2001). Pharmacokinetic/ pharmacodynamic modelling of antipyretic and anti-inflammatory effects of naproxen in the rat. J Pharmacol Exp Ther 297 : 198 205.
25. Karlsson MO, Holford NH (2008). A tutorial on Visual Predictive Checks. Page 17 (2008= Abstract 1434). Available at: http://www.page-meeting.org/? abstract=1434 (accessed 24 September 2009).
26. Kellstein D, Ott D, Jayawardene S, Fricke J (2004). Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Int J Clin Pract 58 : 244 250.
27. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C (2004). Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 32 : 566 571.
28. MHRA Medicines and Healthcare products Regulatory Agency (2005). UK Public Assessment Report for Prexige 100 mg tablets (Lumiracoxib) PL 00101/0677. Available at: http://www.mhra.gov.uk/home/idcplg?IdcService=GET- FILE&dDocName=con2022707&RevisionSelectionMethod=Latest (accessed 24 July 2009).
29. Mysler E (2004). Lumiracoxib (Prexige®): a new selective COX-2 inhibitor. Int J Clin Pract 58 : 606 611.
30. Nantel F, Denis D, Gordon R, Northey A, Cirino M, Metters KM et al. (1999). Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br J Pharmacol 128 : 853 859.
31. Ortiz MI, Castañeda-Hernández G (2008). Examination of the interaction between peripheral lumiracoxib and opioids on the 1% formalin test in rats. Eur J Pain 12 : 233 241.
32. Rordorf CM, Choi L, Marshall P, Mangold JB (2005). Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinetic 44 : 1247 1266. (Pubitemid 41832566)
33. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S et al. (2004). Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 43 : 467 478.
34. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W et al. (1994). Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91 : 12013 12017.
35. Selg E, Buccellati C, Andersson M, Rovati GE, Ezinga M, Sala A et al. (2007). Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol 152 : 1185 1195.
36. Sheiner LB, Ludden TM (1992). Population pharmacokinetics/dynamics. Ann Rev. Pharmacol Toxicol 32 : 185 209.
37. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979). Simultaneous modelling of pharmacokinetics andpharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25 : 358 371.
38. Shi S, Klotz U (2008). Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur Clin Pharmacol 64 : 233 252.
39. Thomas DW, Rocha PN, Nataraj C, Robinson LA, Spurney RF, Koller BH et al. (2003). Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. J Immunol 171 : 6389 6395.
40. Trocóniz IF, Armenteros S, Planelles MV, Bennie J, Calvo R, Domínguez R (2000). Pharmacokinetic-pharmacodynamic modelling of the antipyretic effect of two oral formulations of ibuprofen. Clin Pharmacokinet 38 : 505 518.
41. Van Der Graaf PH, Danhof M (1997). Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther 35 : 442 446.
42. Van Der Graaf PH, Van Schaick EA, Math-ot RA, Ijzerman AP, Danhof M (1997). Mechanism-based pharmacokinetic-pharmacodynamic modelling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther 283 : 809 816.
43. Van der Graaf PH, Van Schaick EA, Visser SA, De Greef HJ, Ijzerman AP, Danhof M (1999). Mechanism-based pharmacokinetic-pharmacodynamic modelling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J Pharmacol Exp Ther 290 : 702 709.
44. Vane JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 231 : 232 235.
45. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK (1998). Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 115 : 101 109.
46. Wallace JL, Chapman K, McKnight W (1999). Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 126 : 1200 1204.
47. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 9 : 7563 7568.
48. Weaver ML, Flood DJ, Kimble EF, Fujimoto RA (2003). Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. Ann Rheum Dis 62 (Suppl. 1 378.
49. Wise ME (1985). Negative power functions of time in pharmacokinetics and their implications. J Pharmacokinet Biopharm 13 : 309 346.
50. Zimmermann M (1983). Ethical guidelines for investigations on experimental pain in conscious animals. Pain 16 : 109 110.